Rhythm begins long-term study of oral bivamelagon for hypothalamic obesity
An oral pill would replace a daily injection for a rare form of obesity, but bivamelagon is not approved and the study is enrolling by invitation only [1].
Rhythm Pharmaceuticals has begun enrolling participants by invitation in a long-term study of bivamelagon, an investigational oral MC4R agonist for hypothalamic obesity [1]. Bivamelagon is not approved by the Food and Drug Administration, and the study, listed on ClinicalTrials.gov as NCT07156578, is not open to general enrollment [1].
The registry entry is titled "A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)" [1]. It is a phase 2 study, a stage of testing that typically follows small early safety studies and looks at whether a drug does what researchers hope it will [1]. The listing describes the study as long term, meaning treatment and follow-up stretch beyond a first round of testing; how many months or years that covers has not been reported [1].
Several basic details are not in the registry record. The number of participants the study plans to enroll has not been reported, and neither have the number of study sites, where those sites are, the dose being tested, or the date the study is expected to finish [1]. Eligibility criteria — the rules about who can and cannot join — have not been disclosed [1]. The record also does not say whether participants will receive bivamelagon alone or with other treatments, or whether any participants will get a placebo [1].
For patients with hypothalamic obesity, the practical comparison is a pill against a shot. The only approved medicine in this drug class is a daily injection, and it can be used in children as young as 4 [1]. That means the option bivamelagon would replace is one that has to be taken every day for a condition that needs long-term treatment [1].
Bivamelagon is not a GLP-1 medication such as semaglutide or tirzepatide. It belongs to a different class, MC4R agonists, which act on a different target in the body [1].
Why it matters for patients
If an oral MC4R agonist works, the main gain would be convenience: no daily needle, which matters most for young children who may need treatment for years [1]. The trade-off is that the drug is still experimental. No results from this study have been reported, so whether a pill controls weight as well as the approved injection is not known [1].
Access is also a question. Because the study is enrolling by invitation, patients cannot simply sign up for it, and the eligibility rules that would explain who is being invited have not been disclosed [1]. Nothing in the record indicates whether the drug would be affordable or covered by insurance if it were eventually approved; that has not been disclosed [1].
Long-term safety also remains open. How the drug performs over years of use, and what side effects appear over that period, have not been established for bivamelagon [1].
What happens next
The study is listed as enrolling by invitation [1]. A primary completion date, a results timeline and any plan for a larger phase 3 trial have not been reported [1]. It is also not known when, or whether, Rhythm would seek FDA approval for bivamelagon in hypothalamic obesity [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.